Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06191198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Communication Bridge 3 Study

Study acronym: CB3
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Start date: Jul 15, 2024 to Aug 23, 2024v9
  3. Re-verified, no change to tracked fieldsv8
  4. Start date changed from estimate of Aug 31, 2024 to Jul 15, 2024v7
  5. Start date: Jul 31, 2024 to Aug 31, 2024v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary endpoints: 1 to 3
    • Primary and study completion dates: Sep 2028 to Jul 15, 2028
    • Start date: Jul 15, 2024 to Jul 31, 2024
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v4
  3. Start date: Jun 2024 to Jul 15, 2024v3
  4. Collaborators: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.
Trial Details
NCT Number NCT06191198
Lead Sponsor University of Chicago
Collaborators: Western University, Canada, National Institute on Aging (NIA)
Conditions
(from sponsor)		 Primary Progressive Aphasia
Related terms Alzheimer Disease, Aphasia, Aphasia, Primary Progressive, Communication, Dementia, Frontotemporal Dementia
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov